To align our findings with the existing literature in FXTAS and Parkinson’s disease, we began by evaluating dopamine transporter (DAT) levels in the entire striatum and subsequently focused on dopaminergic neurons in the substantia nigra. Here, SLC6A3 is linked to Parkinson disease.